1Thomas RP, Hellmich MR, Townsend CM Jr, et al. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev, 2003,24: 571-599.
5Smith JP, Fantaskey AP, Zagon IS. Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol, 1995,268:R135-R141.
6Liu CD, Kwan D, Simon N, et al. Synthetic peptide YY analog binds to a cell membrane receptor and delivers fluorescent dye to pancreatic cancer cells. Gastrointest Surg, 2001,5:147-152.
7de Herder WW, Lamberts SW. Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors. Endocrine,2003,20 : 285-290.
8Baselga J. Why the epidermal growth factor receptor? The rational for cancer therapy. Oncologist, 2002,7suppl 4: 2-8.
4Hajri A, Koenig M, Balboni G, Damge C. Expression and characterization of gastrin-releasing peptide receptor in normal and cancerous pancreas.Pancreas, 1996, 12: 25--35.
5Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene,1995, 11: 211--219.
6Kornmann M, Ishiwata T,Itakura J,Tangvoranuntakul P,Beger HG,Korc M.. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology, 1998,55:363-369.
7Qin Y, Ertl T, Cai RZ, Halmos G, Schally AV. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res, 1994,54: 1035-- 1041.
8Avis I, Jett M, Kasprzyk PG, Cuttitta F, Treston AM, Maneckjee R, Mulshine JL. Effect of gastrin-releasing peptide on the pancreatic tumor cell line (Capan). Mol Carcinog, 1993, 8: 214--220.
9Wang QJ, Knezetic JA, Schally AV, Pour PM, Adrian TE. Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway. Int J Cancer, 1996, 68: 528--534.
10Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest, 1998, 101:344- 352.
